KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,374,124 | +9.1% | 142,692 | +1.9% | 0.16% | -17.9% |
| Q2 2023 | $1,260,000 | +14.5% | 140,000 | 0.0% | 0.20% | -19.6% |
| Q1 2023 | $1,100,400 | +87.8% | 140,000 | +252.4% | 0.25% | +224.7% |
| Q1 2022 | $586,000 | +21.1% | 39,730 | +8.6% | 0.08% | +6.9% |
| Q4 2021 | $484,000 | -71.3% | 36,576 | -62.1% | 0.07% | -39.5% |
| Q3 2021 | $1,685,000 | -27.5% | 96,576 | -0.4% | 0.12% | -36.7% |
| Q2 2021 | $2,323,000 | -69.6% | 96,965 | -67.3% | 0.19% | -26.8% |
| Q1 2021 | $7,629,000 | -66.8% | 296,965 | -75.4% | 0.26% | -74.6% |
| Q4 2020 | $22,965,000 | +47.6% | 1,209,461 | -2.1% | 1.01% | -10.0% |
| Q3 2020 | $15,554,000 | +15.5% | 1,235,471 | +11.0% | 1.13% | +5.0% |
| Q2 2020 | $13,472,000 | +86.0% | 1,113,395 | +17.6% | 1.07% | +96.7% |
| Q1 2020 | $7,242,000 | +91.4% | 946,605 | +345.6% | 0.54% | -11.1% |
| Q4 2019 | $3,783,000 | – | 212,420 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |